Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Pediatrics > Virtual reality vision therapy shows modest improvement in children with intermittent exotropia
  • Pediatrics

Virtual reality vision therapy shows modest improvement in children with intermittent exotropia

Ophthalmology 360

Key Takeaways

  1. A 12-week home-based virtual reality vision therapy program led to modest improvement in distance exotropia control compared with observation.
  2. Greater improvement was seen in children who completed more than 75% of the VRVT training sessions.

A 12-week home-based virtual reality vision therapy (VRVT) program produced modest improvement in distance exotropia control in children with intermittent exotropia (IXT), according to a study, although greater improvement was seen among those who maintained high adherence to the therapy.

The study included 177 children with previously untreated IXT, a distance exodeviation of 10 to 30 prism diopters, exotropia control scores of 1 to 3 at both distance and near, and cycloplegic spherical equivalents ranging from −6.00 to +0.50 diopters in each eye, randomized to either a home-based VRVT program for 12 weeks or an observation-only control group. The full analysis set included 161 children with a median age of 8 years.

By week 12, the median distance control score improved by 0.33 points compared to baseline in the VRVT group, while no change was observed in the control group.

Participants who completed more than 75% of the VRVT training sessions showed greater improvement, with a 0.71-point greater reduction in distance control score than the control group.

Children with baseline distance exotropia control scores≥2 showed greater improvement than those with a baseline score of 1, who showed minimal change.

No adverse events related to the intervention were reported during the treatment phase. The follow-up phase of the trial is ongoing to assess longer-term outcomes.

Reference

Jing Y, Li L, Li Z, et al. Virtual Reality-Based Vision Therapy for Intermittent Exotropia: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(3):e260631. doi: 10.1001/jamanetworkopen.2026.0631. PMID: 41801202.

Share

Related Content

  • Pediatrics

FDA authorization of Stellest leads to an increase in searches for pediatric myopia-control spectacles

  • Glaucoma

Glaucoma drainage devices provide meaningful IOP control in pediatric glaucoma

  • Retina Care 360

Cost analysis shows greater losses for pediatric versus adult retinal detachment repairs

  • Glaucoma

PreserFlo MicroShunt shows short-term benefit in refractory childhood glaucoma

  • Practice Management

New review highlights urgent need to tackle adherence gaps in eye care throughout the patient life cycle

  • Myopia

Dietary patterns linked to myopia risk in children and adolescents

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon